5-Bromo-2,4-difluorotoluene | CAS:159277-47-1

We serve 5-Bromo-2,4-difluorotoluene CAS:159277-47-1 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
5-Bromo-2,4-difluorotoluene

Product Name: 5-Bromo-2,4-difluorotoluene
Other Name: 1-Bromo-2,4-difluoro-5-methylbenzene;2,4-Difluoro-5-methylbromobenzene
CAS No: 159277-47-1
MF: C7H5BrF2
MW: 207.01500
Density: 1.6±0.1 g/cm3
Boiling point: 175.1±35.0 °C at 760 mmHg
Flash point: 59.7±25.9 °C
Refractive index: 1.507
Vapor Pressure: 1.6±0.3 mmHg at 25°C
UN Number: N.A
UN Proper Shipping Name: N.A
Transport hazard class: N.A
Packing group: N.A
 
Specification
Appearance: Colorless to light yellow transparent liquid
Purity: ≥98%
Water: ≤0.5%
 
Application: Organic intermediates, pharmaceutical intermediates.
Package: 25kg/drum, packed in plastic drum or plastic coated iron drum.
Storage: Store in cool place. Keep container tightly closed in a dry and well-ventilated place.



Contact us for information like 5-Bromo-2,4-difluorotoluene chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,2,4-Difluoro-5-methylbromobenzene physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,5-Bromo-2,4-difluorotoluene Use and application,1-Bromo-2,4-difluoro-5-methylbenzene technical grade,usp/ep/jp grade.


Related News: CMO services mainly involve four stages: pre-clinical research, clinical trials, sales of patented drugs after listing, and sales of original drug products after patents expire. Its advantages are: lower cost, guaranteed quality, good capacity flexibility, and favorable process Promotion.2-Ethyl anthraquinone manufacturer Subsequently, the company launched the drug under the brand names ‘Remo’ and ‘Remozen’.6-Cyano-N,N,2-trimethyl-7-oxo-4,8-dioxa-2,5-diazadec-5-en-3-aminium hexafluorophosphate supplier Different cell types can be affected, although the most common finding in MDS is a shortage of red blood cells (anaemia). Patients with higher-risk MDS may progress to the development of acute leukaemia.4,4-Dimethyl-1,2-oxazolidin-3-one vendor The ban will be in place for up to 14 days, and is aimed at helping contain the spread of the Wuhan coronavirus. So far, there have been no confirmed coronavirus cases in New Zealand or any South Pacific island.The ban will be in place for up to 14 days, and is aimed at helping contain the spread of the Wuhan coronavirus. So far, there have been no confirmed coronavirus cases in New Zealand or any South Pacific island.